AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2024

May 17, 2024

31565_dirs_2024-05-17_21e95a2b-951a-4105-8271-a70e069c5cb2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-05-15

Reporting Person: Llorens Josep (EVP, Global Manufacturing)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-15	Common Stock	F	258	$96.49	Disposed	18205	Direct
2024-05-16	Common Stock	F	263	$94.80	Disposed	17942	Direct
2024-05-16	Common Stock	S	770	$96.14	Disposed	17172	Direct

Footnotes

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported.

F3: Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023).